Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Reyer-Igama

157P Second-Line Afatinib for Patients With Locally Advanced or Metastatic NSCLC Harbouring Common EGFR Mutations: A Phase IV Study

Journal of Thoracic Oncology

English

Related publications

Afatinib in Locally Advanced/Metastatic NSCLC Harboring Common EGFR Mutations, After Chemotherapy: A Phase IV Study

Lung Cancer Management

2019

English

P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology

English

140PD: LUX-Lung 7: A Phase IIb, Global, Randomised, Open-Label Trial of Afatinib vs Gefitinib as First-Line Treatment for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring Activating EGFR Mutations

Journal of Thoracic Oncology

English

First-Line Treatment in NSCLC Harboring EGFR Common Mutations: EGFR TKI in Monotherapy or in Combination With Anti-Vegf?

Expert Review of Anticancer Therapy

Oncology

Pharmacology

2016

English

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

Wspolczesna Onkologia

English

First-Line Osimertinib in Patients With Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC

Journal of Thoracic Oncology

English

OA03 Afatinib Followed by Osimertinib in Real-World Patients With EGFR Mutation-Positive Advanced NSCLC: The Giotag Study

Journal of Thoracic Oncology

English

Fludarabine Combined With Radiotherapy in Patients With Locally Advanced NSCLC Lung Carcinoma: A Phase I Study

Journal of Cancer Research and Clinical Oncology

English

P3.01-54 a Historical Comparison of Patients With Advanced NSCLC Harboring Uncommon EGFR Mutations Before and After the Approval of Afatinib in Japan

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Reyer-Igama

157P Second-Line Afatinib for Patients With Locally Advanced or Metastatic NSCLC Harbouring Common EGFR Mutations: A Phase IV Study

Related publications

Afatinib in Locally Advanced/Metastatic NSCLC Harboring Common EGFR Mutations, After Chemotherapy: A Phase IV Study

P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations

140PD: LUX-Lung 7: A Phase IIb, Global, Randomised, Open-Label Trial of Afatinib vs Gefitinib as First-Line Treatment for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring Activating EGFR Mutations

First-Line Treatment in NSCLC Harboring EGFR Common Mutations: EGFR TKI in Monotherapy or in Combination With Anti-Vegf?

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

First-Line Osimertinib in Patients With Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC

OA03 Afatinib Followed by Osimertinib in Real-World Patients With EGFR Mutation-Positive Advanced NSCLC: The Giotag Study

Fludarabine Combined With Radiotherapy in Patients With Locally Advanced NSCLC Lung Carcinoma: A Phase I Study

P3.01-54 a Historical Comparison of Patients With Advanced NSCLC Harboring Uncommon EGFR Mutations Before and After the Approval of Afatinib in Japan